News

 

 

'The enemy of my enemy is my friend:' Couple turns to viruses to beat back superbug

By Amina Zafar, CBC News Posted: Apr 28, 2017 8:14 PM ET Last Updated: Apr 29, 2017 7:32 AM ET - Link here

Read more about 'The enemy of my enemy is my friend:' Couple turns to viruses to beat back superbug

Avita Medical Announces Positive Results from Pivotal Trial

Highlights

Read more about Avita Medical Announces Positive Results from Pivotal Trial

Adherium wins “Most Innovative Hi-Tech Hardware Product Award’ at the 2017 NZ High Tech Awards

15/05/2017 - link here

Read more about Adherium wins “Most Innovative Hi-Tech Hardware Product Award’ at the 2017 NZ High Tech Awards

AmpliPhi Biosciences Reports First Quarter 2017 Financial Results and Provides Business Highlights

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a leader in the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces financial results for the quarter ended March 31,...

Read more about AmpliPhi Biosciences Reports First Quarter 2017 Financial Results and Provides Business Highlights

Avita Medical initiates legal proceedings to cancel Renovacare patent

Valencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, 11 May 2017 — link here

Read more about Avita Medical initiates legal proceedings to cancel Renovacare patent

Initial Pre-Emergency Use Authorization submission made to U.S. FDA for use of ReCell® in a Mass Casualty Scenario

Valencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, 10 May 2017 — link here

Read more about Initial Pre-Emergency Use Authorization submission made to U.S. FDA for use of ReCell® in a Mass Casualty Scenario

AmpliPhi Biosciences Announces Closing of Public Offering

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a biotechnology company focused on the development of therapies for drug-resistant bacterial infections using bacteriophage technology, today announced the closing of its...

Read more about AmpliPhi Biosciences Announces Closing of Public Offering

AmpliPhi Biosciences Announces Pricing of $10.4 Million Underwritten Public Offering of Common Stock and Common Warrants

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a biotechnology company focused on the development of therapies for drug-resistant bacterial infections using bacteriophage technology, today announced the pricing of an...

Read more about AmpliPhi Biosciences Announces Pricing of $10.4 Million Underwritten Public Offering of Common Stock and Common Warrants

AmpliPhi Biosciences Announces a New Strategic Emphasis on Personalized Therapies for Serious or Life-Threatening Antibiotic-Resistant Infections

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a leader in the field of bacteriophage technology, announces a new strategic emphasis on precisely targeted and personalized medicines designed to address...

Read more about AmpliPhi Biosciences Announces a New Strategic Emphasis on Personalized Therapies for Serious or Life-Threatening Antibiotic-Resistant Infections

AmpliPhi Biosciences Announces Presentation of Personalized Bacteriophage Therapy Case Study for Life-Threatening Antibiotic-Resistant Infection at Scientific Conference

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies for drug-resistant bacterial infections using bacteriophage technology, announces that a case study highlighting the...

Read more about AmpliPhi Biosciences Announces Presentation of Personalized Bacteriophage Therapy Case Study for Life-Threatening Antibiotic-Resistant Infection at Scientific Conference

1 2 3 4 ... 25